The Medicaid Drug Rebate Program (MDRP) is a pivotal component of the U.S. healthcare system, requiring drug manufacturers to offer rebates on outpatient drugs to state Medicaid programs. J. Molner said in a market notice published earlier this week. In exchange, states provide coverage for these drugs for their respective Medicaid enrollees.

This latest deal will see J. Molner provide rebates to all states with Medicaid state plans, the company continued, noting that this program is vital for ensuring the accessibility of essential medications to low-income populations.

"As a generic pharmaceutical company, this agreement not only amplifies our impact on public health by making our medications more accessible to a wider audience, but also solidifies our commitment to supporting the U.S. healthcare system," the company said, describing its participation in the rebate program as a strategic milestone.

"By offering rebates, we are ensuring that our products are both affordable and available to the populations who need them the most," they added.

Implementation of the Estonian company's participation across all U.S. states is underway, with each state adopting their Molner rebate program in phases. According to the company, the process is expected to be fully complete by the end of the month.

CMS is the federal U.S. agency that provides health coverage to more than 160 million people through Medicare, Medicaid, the Children's Health Insurance Program (CHIP) as well as the Health Insurance Marketplace.

J. Molner AS is listed on Nasdaq Tallinn's alternative First North market.

--

Follow ERR News on Facebook and Twitter and never miss an update!